Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Multiple Rising Inhaled Doses of BI 1265162
NCT03576144Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in cystic fibrosis (CF) comparing BI 1265162 with Placebo (2 arms). Primary endpoint: Percentage of Participants With Drug-related Adverse Events up to 10 days. Started Jul 2018; status: completed.
02
Drugs
BI 1265162
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03576144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03576144.